

Supplementary Materials for

Human pluripotent stem cell–derived brain pericyte–like cells induce blood-brain barrier properties

Matthew J. Stebbins, Benjamin D. Gastfriend, Scott G. Canfield, Ming-Song Lee, Drew Richards, Madeline G. Faubion, Wan-Ju Li, Richard Daneman, Sean P. Palecek*, Eric V. Shusta*

*Corresponding author. Email: eshusta@wisc.edu (E.V.S.); sppalecek@wisc.edu (S.P.P.)

Published 13 March 2019, *Sci. Adv.* **5**, eaau7375 (2019)
DOI: 10.1126/sciadv.aau7375

The PDF file includes:

- Fig. S1. Generation of multipotent NCSC populations from multiple hPSC lines.
- Fig. S2. Serum treatment directs iPSC-derived NCSCs toward mural cells.
- Fig. S3. Supplemental analysis of hPSC-derived pericyte-like cells.
- Fig. S4. Supplemental analysis of BMEC/hPSC-derived pericyte-like cell cocultures.
- Fig. S5. Measurement of the effects of hPSC-derived pericyte-like cells on primary rat BMEC phenotypes.
- Fig. S6. NCSCs maintained in E6-CSFD retain neural crest marker expression and do not develop pericyte marker expression.
- Fig. S7. hPSC-derived pericyte-like cell assembly with brain endothelial cells.
- Table S1. Antibody staining conditions and DNA primer sequences and running conditions.
- Table S2. Pericyte-enriched genes identified by single-cell RNA-seq in mouse (40) with human homologs

Other Supplementary Material for this manuscript includes the following:

(available at advances.sciencemag.org/cgi/content/full/5/3/eaau7375/DC1)

Table S3. (Microsoft Excel format). RNA-seq FPKM data for all samples.













Fig. S1. Generation of multipotent NCSC populations from multiple hPSC lines. A) Immunocytochemistry images of small molecule screen (n = 1) on HNK1 and p75-NGFR expression in cells differentiated from H9 hESCs. Cells were cultured fifteen days in E6 + 10 ng/mL FGF2 + 22.5 µg/mL heparin + 10 µM SB431542 + CHIR99012 ± dorsomorphin at the indicated concentrations. Hoechst nuclear counter stain (blue) is also included. Scale bars: 100 µm. B) Immunocytochemistry images of IMR90C4 iPSCs differentiated in E6-CSFD probed for the presence of HNK1 and p75-NGFR at D15. Hoechst nuclear counter stain (blue) is also included. Scale bars: 100 µm. C) Immunocytochemistry images of CS03n2 iPSCs differentiated in E6-CSFD probed for the presence of HNK1 and p75-NGFR at D15. Hoechst nuclear counter stain (blue) is also included. Scale bars: 100 µm. D) AP-2 immunocytochemistry images for IMR90C4-derived NCSCs at D15. Hoechst nuclear counter stain (blue) is also included. Scale bar: 100 µm. E) AP-2 immunocytochemistry images for CS03n2-derived NCSCs at D15. Hoechst DNA nuclear stain (blue) is also included. Scale bar: 100 µm. F) Temporal PCR analysis of pluripotency (*NANOG*, *POU5F1*) and NCSC (*TFAP2A*, *B3GAT1*, *NGFR*, *SOX9*, *SOX10*) transcripts in IMR90C4 and CS03n2 iPSCs and NCSC progeny. G) Flow cytometry analysis of IMR90C4-derived NCSCs. Panels include NCSC (HNK1⁺/p75-NGFR⁺) purity prior to MACS (panel i), and NCSC purity following MACS (panel ii). Inset percentages are included in each quadrant. Quantitation is shown in Table 1. H) Flow cytometry analysis of CS03n2-derived NCSCs. Panels include NCSC (HNK1⁺/p75-NGFR⁺) purity prior to MACS (panel i), and NCSC purity following MACS (panel ii). Inset percentages are included in each quadrant. Quantitation is shown in Table 1. I) Immunocytochemistry analysis of IMR90C4-derived NCSCs subsequently differentiated in peripheral neuron medium. Resultant cells were positive for βIII-tubulin and peripherin expression. Hoechst nuclear counter stain (blue) is also included. Scale bar: 100 µm. J) IMR90C4-derived NCSCs could be differentiated into mesenchymal derivatives, including Oil Red O stained adipocytes (panel i, red), Alizarin red stained osteocytes (panel ii, red), and Alcian blue stained chondrocytes (panel ii, blue).









Fig. S2. Serum treatment directs iPSC-derived NCSCs toward mural cells. A, B) Representative PDGFR β and NG2 flow cytometry plots for IMR90C4-derived NCSCs treated for 9 days with E6 + 10% FBS medium. C, D) Representative PDGFR β and NG2 flow cytometry plots for CS03n2-derived NCSCs treated for 9 days with E6 + 10% FBS medium. Quantitative results can be found in Fig. 1J. E) PDGFR β and NG2 immunocytochemistry of IMR90C4-derived NCSCs (D16) and mural cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m. F) Calponin and SM22 α immunocytochemistry of IMR90C4-derived NCSCs (D16) and mural cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m. G) α -SMA immunocytochemistry of IMR90C4-derived NCSCs (D16) and mural cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m. H,I) CD13 and desmin immunocytochemistry of IMR90C4-derived mural cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m. J) PDGFR β and NG2 immunocytochemistry of CS03n2-derived mural cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m. K) Calponin and SM22 α immunocytochemistry of CS03n2-derived mural cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m. L) α -SMA immunocytochemistry of CS03n2-derived mural cells (D22). Hoechst DNA nuclear stain (blue) is also included. Scale bars: 200 μ m. M,N) CD13 and desmin immunocytochemistry of CS03n2-derived pericyte-like cells (D22). Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m. O,P) CD13 and desmin immunocytochemistry of H9-derived NCSCs (D16). Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m. Q,R) CD13 and desmin immunocytochemistry of primary brain pericytes. Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m.





Fig. S3. Supplemental analysis of hPSC-derived pericyte-like cells. A,B) Analysis of cells obtained by culturing NCSCs in E6, E6 + TGF β 1 + PDGF-BB, or E6 + 10% FBS for 6 days. Calponin, SM22 α , and α -SMA immunocytochemistry. Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m. C,D,E) Long-term maintenance of hPSC-derived pericyte-like cells. PDGFR β , NG2, calponin, SM22 α , and α -SMA immunocytochemistry of H9-derived pericyte-like cells maintained in E6 + 10% FBS to D45. Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μ m. F) Temporal PCR analysis of mural and pericyte transcripts for the differentiating IMR90C4 and CS03n2 iPSC lines.







Fig. S4. Supplemental analysis of BMEC/hPSC-derived pericyte-like cell cocultures. A) PDGFR β and NG2 immunocytochemistry of hPSC-derived pericyte-like cells following 48 hours of co-culture with iPSC-derived BMECs. Hoechst nuclear counter stain (blue) is also included. Images are representative of two independent differentiations. Scale bars: 100 μ m. B) Western blot analysis of occludin and claudin-5 expression in iPSC-derived BMECs cultured alone or co-cultured with primary brain pericytes, IMR90C4-derived pericyte-like cells, or 3T3s. Quantification of occludin and claudin-5 expression after normalized to β -actin signal and to monoculture expression levels. Plotted are the means \pm SD from 3 Transwells from a single differentiation. No significant differences by ANOVA. C) Representative images of claudin-5 immunocytochemistry of BMECs cultured for 48 h in EC medium (Mono) or EC medium conditioned by primary brain pericytes or IMR90C4-derived pericyte-like cells. Scale bar: 25 μ m. Quantification of claudin-5 area fraction index and frayed junctions. Plotted are the means \pm SEM of 3 independent differentiations. No significant difference by ANOVA. D) Confocal microscopy of monocultured iPSC-derived BMECs incubated with Alexa 488-tagged 10 kDa dextran (green) with EC medium (Mono) or conditioned medium from primary brain pericytes, IMR90C4-derived pericyte-like cells, or 3T3s. Total dextran is depicted in green. Surface dextran was labeled with Alexa 647 (red), with little observed signal. Thus, the observed green signal is a result of internalized dextran. Hoechst nuclear counter stain (blue) is also included. Scale bar: 10 μ m.






Fig. S5. Measurement of the effects of hPSC-derived pericyte-like cells on primary rat BMEC phenotypes. A) TEER profile of primary rat BMECs either in monoculture or co-culture with primary brain pericytes, IMR90C4-derived pericyte-like cells, or 3T3s. Plotted are means \pm SD of three Transwells from a single rat BMEC isolation. * $P < 0.05$ IMR90C4-derived pericyte-like cell co-culture vs. monoculture; # $P < 0.05$ primary pericyte co-culture vs. monoculture; ANOVA followed by Dunnett's test. B,C) Accumulation (B) or transcytosis (C) of Alexa 488-tagged 10 kDa dextran in primary rat BMECs following co-culture with cell types as described in A. All results normalized to BMEC monoculture control. Plotted are the means \pm SD of 3 Transwells from a single rat BMEC isolation. * $P < 0.05$ vs. monoculture; ANOVA followed by Dunnett's test.


A



B



C



D




Fig. S6. NCSCs maintained in E6-CSFD retain neural crest marker expression and do not develop pericyte marker expression. A) Expression (FPKM) of selected transcripts in D15 NCSCs, D55 NCSCs (maintained in E6-CSFD for an additional 40 days), and all D25 pericyte-like cell samples (“H”). B) p75-NGFR immunocytochemistry analysis of NCSCs maintained in E6-CSFD for 3 months. Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m. C) NG2 immunocytochemistry analysis of NCSCs maintained in E6-CSFD for 3 months. Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m. D) NG2 immunocytochemistry analysis of H9-derived D22 pericyte-like cells, processed alongside and identically to the NCSC sample above. Hoechst nuclear counter stain (blue) is also included. Scale bar: 200 μ m.




Fig. S7. hPSC-derived pericyte-like cell assembly with brain endothelial cells. A) Self-assembly schematic. hPSC-derived pericyte-like cells self-assemble with hBMECs to form vascular cords. B) Confocal immunocytochemistry images of primary pericytes and H9-derived pericyte-like cells (NG2) aligning with and extending processes along hBMEC cords (CD31). Hoechst nuclear counter stain (blue) is also included. Scale bars: 50 µm. C) Immunocytochemistry images of hBMECs alone or cultured with HEK293 fibroblasts (+HEK293), primary human brain pericytes (+Primary Pericytes), CS03n2-derived pericyte-like cells (+CS03n2), H9-derived pericyte-like cells (+H9), or IMR90C4-derived pericyte-like cells

(+IMR90C4). Hoechst nuclear counter stain (blue) is also included. Scale bars: 200 μm . D) Representative bright field images of HUVECs alone or cultured with the various cell types. Scale bars: 200 μm . E) Quantification of the average segment lengths from bright field images in panel D. Plotted are means \pm SD of three imaging fields from one well. * $P < 0.05$ vs. hBMEC monoculture; ANOVA followed by Dunnett's test. F) Quantification of the number of segments per field normalized to hBMEC monoculture from bright field images in panel D. Plotted are means \pm SD of three imaging fields from one well. * $P < 0.05$ vs. HUVEC monoculture; ANOVA followed by Dunnett's test.

Table S1A. Antibody staining conditions.

Marker	Fixative	App.	Vendor (Clone/Catalog #, Species)	Dilution	Blocking Buffer	Staining Buffer
p75-NGFR	4% PFA	ICC	Advanced Targeting Systems (ME20.4, Mouse IgG ₁)	1:1000	1% BSA	1% BSA
		Flow	Advanced Targeting Systems (ME20.4, Mouse IgG ₁)	0.2 μ L/10 ⁶ cells	N/A	PBS
HNK1	4% PFA	ICC	Sigma (C6608, Mouse IgM)	1:300	1% BSA	1% BSA
		Flow	Sigma (C6608, Mouse IgM)	0.2 μ L/10 ⁶ cells	N/A	PBS
AP2	4% PFA	ICC	DSHB (3B5, Mouse IgG _{2b})	1:50	1% BSA + 0.1% TX-100	1% BSA
Peripherin	4% PFA	ICC	Millipore (AB1530, Rabbit Polyclonal)	1:200	1% BSA + 0.1% TX-100	1% BSA
β III-Tubulin	4% PFA	ICC	Sigma (T8860, Mouse IgG _{2b})	1:500	1% BSA + 0.1% TX-100	1% BSA
NG2	4% PFA	ICC	Millipore (MAB2029, Mouse IgG _{2a})	1:100	5% goat serum + 0.4% TX-100	PBS + 0.4% TX-100
		Flow	Millipore (MAB2029, Mouse IgG _{2a})	2 μ L/10 ⁶ cells	N/A	MACS Buffer
PDGFR β	4% PFA	ICC	Cell Signaling Technology (28E1, Rabbit Monoclonal)	1:100	5% goat serum + 0.4% TX-100	PBS + 0.4% TX-100
		Flow	BD Biosciences (28D4, Mouse IgG _{2a})	1.25 μ L/10 ⁶ cells	N/A	MACS Buffer
CNN1	4% PFA	ICC	Sigma (C2687, Mouse IgG ₁)	1:15000	3% BSA + 0.1% TX-100	3% BSA
SM22 α	4% PFA	ICC	Abcam (ab14106)	1:1000	3% BSA + 0.1% TX-100	3% BSA
CD31	4% PFA	ICC	Thermo Fisher (RB-10333, Rabbit Polyclonal)	1:25	5% goat serum + 0.4% TX-100	PBS + 0.4% TX-100
aSMA	4% PFA	ICC	Lab Vision (MS-113-P)	1:100	5% milk + 0.1% TX-100	5% milk
β -actin	N/A	WB	Cell Signaling Technology (13E5, Rabbit Monoclonal)	1:1000	TBST + 5% milk	TBST + 5% milk
Occludin	MeOH	ICC	Invitrogen (OC-3F10, Mouse IgG ₁)	1:200	10% goat serum	10% goat serum
	N/A	WB	Invitrogen (OC-3F10, Mouse IgG ₁)	1:500	TBST + 5% milk	TBST + 5% milk
Claudin-5	N/A	WB	Invitrogen (4C3C2, Mouse IgG ₁)	1:250	TBST + 5% milk	TBST + 5% milk
CD13	4% PFA	ICC	R&D Systems (MAB3815, Mouse IgG _{2a})	1:50	10% goat serum	10% goat serum
Desmin	MeOH	ICC	Thermo Fisher (RB-9014, Rabbit Polyclonal)	1:50	10% goat serum	10% goat serum

Table S1B. DNA primer sequences and running conditions.

Gene	T _a (°C)	Cycles	Fwd Sequence	Rev Sequence
ABCC9	60	40	5'- TCA ACC TGG TCC CTC ATG TCT -3'	5'- CAG GAG AGC GAA TGT AAG AAT CC -3'
ACTA2	60	30	5'- TGT TCC AGC CAT CCT TCA TC -3'	5'- GCA ATG CCA GGG TAC ATA GT -3'
ANPEP	49	40	5'- GAA GAG AAC TGG AGG AAG ATT CAG -3'	5'- CCA GGT TGA AGG CGT CAT TA -3'
B3GAT1	58	35	5'- TCG CCT GGA CTG GAC TGG GG -3'	5'- TGG CCT TGG CCT CCC TCC TC -3'
CNN1	53	40	5'- GTC CAC CCT CCT GGC TTT -3'	5'- AAA CTT GTT GGT GCC CAT CT -3'
CSPG4	54	35	IDT DNA Hs.PT.58.39417158 Predesigned Probe	
FOXF2	52	40	5'- ACC AGA GCG TCT GTC AGG ATA TT -3'	5'- GTG ACT TGA ATC CGT CCC AGT TTC -3'
GAPDH	60	30	5'- GAA GGT GAA GGT CGG AGT CAA CG -3'	5'- TCC TGG AAG ATG GTG ATG GGA T -3'
KCNJ8	60	40	5'- GTG ATT GCC GTC CGA AAT GG -3'	5'- AGT TGG TGA ATA GGA ACC ACC T -3'
NANOG	58	30	5'- CGA AGA ATA GCA ATG GTG TGA CG -3'	5'- TTC CAA AGC AGC CTC CAA GTC -3'
NGFR	60	30	5'- GTG GGA CAG AGT CTG GGT GT -3'	5'- AAG GAG GGG AGG TGA TAG GA -3'
PDGFRB	53	40	5'- GCT CAC CAT CAT CTC CCT TAT C -3'	5'- CTC ACA GAC TCA ATC ACC TTC C -3'
POU5F1	58	30	5'- CAG TGC CCG AAA CCC ACA C -3'	5'- GGA GAC CCA GCA GCC TCA AA -3'
SOX10	61	40	5'- ATA CGA CAC TGT CCC GGC CCT AAA -3'	5'- TTC TCC TCT GTC CAG CCT GTT CTC -3'
SOX9	60	40	5'- AGC GAA CGC AACA TCA AGA C -3'	5'- CTG TAG GCG ATC TGT TGG GG -3'
TAGLN	51	40	5'- TCT TTG AAG GCA AAG ACA TGG -3'	5'- TTA TGC TCC TGC GCT TTC TT -3'
TBX18	60	40	5'- CCC AGG ACT CCC TCC TAT GT -3'	5'- TAG GAA CCC TGA TGG GTC TG -3'
TFAP2A	50	30	5'- TCC CTG TCC AAG TCC AAC AGC AAT -3'	5'- AAA TTC GGT TTC GCA CAC GTA CCC -3'
ZIC1	59	40	5'- TGG CCC GGA GCA GAG TAA T -3'	5'- CCC TGT GTG CGT CCT TTT G -3'

Table S2. Pericyte-enriched genes identified by single cell RNA-seq in mouse (40) with human homologs.

Gene	FPKM	
	Primary	hPSC-derived
<i>ABCC9</i>	0.3	0.1
<i>AGAP2</i>	0.0	0.0
<i>ANK2</i>	9.6	2.3
<i>ANO4</i>	0.2	2.5
<i>APOD</i>	0.2	0.6
<i>APOE</i>	42.9	25.6
<i>ARHGAP31</i>	3.4	7.6
<i>CORO1B</i>	68.4	56.1
<i>ECE1</i>	58.7	31.0
<i>EMCN</i>	3.3	1.7
<i>FAM118B</i>	0.0	0.0
<i>FBLN1</i>	24.7	112.0
<i>FLT1</i>	4.7	7.6
<i>FOXF2</i>	4.4	0.9
<i>GGT1</i>	104.8	181.9
<i>GPR4</i>	5.4	4.6
<i>IFI30</i>	18.4	17.2
<i>IGF2</i>	0.3	14.0
<i>ITIH5</i>	2.6	0.2
<i>ITM2A</i>	0.3	3.9
<i>JUP</i>	6.4	20.8
<i>KCNJ8</i>	0.8	0.3
<i>LGALS9</i>	5.1	3.4
<i>NODAL</i>	0.1	0.1
<i>NRXN2</i>	2.5	0.8
<i>NXPH4</i>	30.3	0.4
<i>PCDHGC3</i>	0.0	0.0
<i>PDE2A</i>	0.6	0.1
<i>PDE8A</i>	6.5	6.0
<i>PHC1</i>	0.0	10.8
<i>PHLDB1</i>	28.5	28.8
<i>PLOD1</i>	189.1	145.8
<i>POR</i>	33.4	28.4
<i>PPP1CC</i>	40.7	82.8
<i>PREX2</i>	0.0	0.0
<i>SEPP1 (SELENOP)</i>	19.8	1.4
<i>SFRP2</i>	0.0	16.7
<i>SLC22A8</i>	0.0	0.0
<i>SLC6A13</i>	0.4	0.1
<i>SPP1</i>	0.96	11.6
<i>ST8SIA4</i>	0.0	0.3
<i>SYNE1.2 (SYNE1)</i>	16.9	6.0
<i>TNFRSF19</i>	0.4	13.6
<i>TRPC3</i>	0.2	0.1
<i>TTLL3</i>	160.3	210.9
<i>UCHL1</i>	739.1	415.9
Number with FPKM \geq 1	26	29

*Average of all D25 hPSC-derived pericyte-like cell differentiations (H9 A-C, CS03n2 and IMR90C4)